Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity

Toxicology and Applied Pharmacology

Volumn 273, Issue 3, 2013, Pages 500-507

  Sirenko, Oksana ^a   Cromwell, Evan F ^a   Crittenden, Carole ^a   Wignall, Jessica A ^b   Wright, Fred A ^c   Rusyn, Ivan ^b  

^a MOLECULAR DEVICES CORPORATION   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c IL   (United States)

Author keywords

Calcium flux; Cardiotoxicity; HERG; IPSC; Phenotypic screening; Predictive toxicology

Indexed keywords

ARSENIC TRIOXIDE; BORTEZOMIB; BUSULFAN; CALCIUM ION; CARBAMAZEPINE; CYTARABINE; DILTIAZEM; DIMETHYL SULFOXIDE; EPHEDRINE; FELBAMATE; FLUOROURACIL; GEMCITABINE; HYDRALAZINE; IBUPROFEN; IFOSFAMIDE; INDINAVIR; INDOMETACIN; LEVOFLOXACIN; LITHIUM CITRATE; MELOXICAM; MELPHALAN; MILNACIPRAN; PREDNISONE; PROBUCOL; ROFECOXIB; ROSIGLITAZONE; SILDENAFIL NITRATE; THEOPHYLLINE; UNINDEXED DRUG; ZIDOVUDINE;

ARTICLE; CALCIUM TRANSPORT; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CELL FUNCTION; CELL SCREENING; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EXPOSURE; DRUG SCREENING; HEART BEAT; HEART MUSCLE CELL; HEART RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PLURIPOTENT STEM CELL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; TOXICOLOGICAL PARAMETERS;

AREA UNDER THE CURVE; AUC; BENCHMARK CONCENTRATION; BMC; CALCIUM FLUX; CARDIOTOXICITY; DIMETHYL SULFOXIDE; DMSO; EC(50); EFFECTIVE CONCENTRATION AT 50% OF THE MAXIMUM RESPONSE; HERG; INDUCED PLURIPOTENT STEM CELL; IPSC; PHENOTYPIC SCREENING; PREDICTIVE TOXICOLOGY;

AREA UNDER CURVE; CARDIOTOXINS; CELL SURVIVAL; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEART DISEASES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC; PHENOTYPE; RISK ASSESSMENT;

EID: 84888861133     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.09.017     Document Type: Article

References (29)

1. Alvarez P.A., Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr. Drug Saf. 2010, 5:97-104.
2. Anson B.D., Kolaja K.L., Kamp T.J. Opportunities for use of human iPS cells in predictive toxicology. Clin. Pharmacol. Ther. 2011, 89:754-758.
3. Arias C., Guizy M., David M., Marzian S., Gonzalez T., Decher N., Valenzuela C. Kvbeta1.3 reduces the degree of stereoselective bupivacaine block of Kv1.5 channels. Anesthesiology 2007, 107:641-651.
4. Bers D.M. Cardiac excitation-contraction coupling. Nature 2002, 415:198-205.
5. Cerignoli F., Charlot D., Whittaker R., Ingermanson R., Gehalot P., Savchenko A., Gallacher D.J., Towart R., Price J.H., McDonough P.M., Mercola M. High throughput measurement of Ca(2)(+) dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. J. Pharmacol. Toxicol. Methods 2012, 66:246-256.
6. EPA Benchmark Dose Technical Guidance 2012, US Environmental Protection Agency, Washington, DC.
7. Fawcett T. An introduction to ROC analysis. Pattern Recogn. Lett. 2006, 27:861-874.
8. Frid A.A., Matthews E.J. Prediction of drug-related cardiac adverse effects in humans-B: use of QSAR programs for early detection of drug-induced cardiac toxicities. Regul. Toxicol. Pharmacol. 2010, 56:276-289.
9. Guo L., Abrams R.M., Babiarz J.E., Cohen J.D., Kameoka S., Sanders M.J., Chiao E., Kolaja K.L. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 2011, 123:281-289.
10. Gwanyanya A., Macianskiene R., Mubagwa K. Insights into the effects of diclofenac and other non-steroidal anti-inflammatory agents on ion channels. J. Pharm. Pharmacol. 2012, 64:1359-1375.
11. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
12. Laverty H., Benson C., Cartwright E., Cross M., Garland C., Hammond T., Holloway C., McMahon N., Milligan J., Park B., Pirmohamed M., Pollard C., Radford J., Roome N., Sager P., Singh S., Suter T., Suter W., Trafford A., Volders P., Wallis R., Weaver R., York M., Valentin J. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. Br. J. Pharmacol. 2011, 163:675-693.
13. Lawrence C.L., Pollard C.E., Hammond T.G., Valentin J.P. In vitro models of proarrhythmia. Br. J. Pharmacol. 2008, 154:1516-1522.
14. Liang P., Lan F., Lee A.S., Gong T., Sanchez-Freire V., Wang Y., Diecke S., Sallam K., Knowles J.W., Nguyen P.K., Wang P.J., Bers D.M., Robbins R.C., Wu J.C. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease specific patterns of cardiotoxicity. Circulation 2013, 127:1677-1691.
15. Ma J., Guo L., Fiene S.J., Anson B.D., Thomson J.A., Kamp T.J., Kolaja K.L., Swanson B.J., January C.T. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H2006-H2017.
16. Mercola M., Colas A., Willems E. Induced pluripotent stem cells in cardiovascular drug discovery. Circ. Res. 2013, 112:534-548.
17. Neubig R.R., Spedding M., Kenakin T., Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol. Rev. 2003, 55:597-606.
18. Pointon A., Abi-Gerges N., Cross M.J., Sidaway J.E. Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity. Toxicol. Sci. 2013, 132:317-326.
19. Puppala D., Collis L.P., Sun S.Z., Bonato V., Chen X., Anson B., Pletcher M., Fermini B., Engle S.J. Comparative gene expression profiling in human-induced pluripotent stem cell-derived cardiocytes and human and cynomolgus heart tissue. Toxicol. Sci. 2013, 131:292-301.
20. 2+ dynamics in cultured Guinea pig cardiomyocytes as an in vitro model to identify potential cardiotoxicants. Toxicol. in Vitro 2010, 24:960-972.
21. Rana P., Anson B., Engle S., Will Y. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. Toxicol. Sci. 2012, 130:117-131.
22. Reif D.M., Sypa M., Lock E.F., Wright F.A., Wilson A., Cathey T., Judson R.R., Rusyn I. ToxPi GUI: an interactive visualization tool for transparent integration of data from diverse sources of evidence. Bioinformatics 2013, 29:402-403.
23. + to analyze and compare ROC curves. BMC Bioinforma. 2011, 12:77.
24. Rusyn I., Sedykh A., Low Y., Guyton K.Z., Tropsha A. Predictive modeling of chemical hazard by integrating numerical descriptors of chemical structures and short-term toxicity assay data. Toxicol. Sci. 2012, 127:1-9.
25. Sand S., Ringblom J., Hakansson H., Oberg M. The point of transition on the dose-effect curve as a reference point in the evaluation of in vitro toxicity data. J. Appl. Toxicol. 2012, 32:843-849.
26. Scott C.W., Peters M.F., Dragan Y.P. Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. Toxicol. Lett. 2013, 219:49-58.
27. Sirenko O., Crittenden C., Callamaras N., Hesley J., Chen Y.W., Funes C., Rusyn I., Anson B., Cromwell E.F. Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells. J. Biomol. Screen. 2013, 18:39-53.
28. Taboureau O., Jorgensen F.S. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology. Comb. Chem. High Throughput Screen. 2011, 14:375-387.
29. Williams P.D. The role of pharmacological profiling in safety assessment. Regul. Toxicol. Pharmacol. 1990, 12:238-252.